What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The final products of MASCT-I technology are dendritic cells (DC) and effector T cells.”In the company’s words, NCT06277154 on ClinicalTrials.gov
- Tested for
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Fibrosarcoma and 3 more
- Main trialPhase 2
- “This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.”In the company’s words, NCT06277154 on ClinicalTrials.gov
Other drugs for Leiomyosarcoma
- AL3818Advenchen Laboratories, LLC · Phase 3
- LurbinectedinJazz Pharmaceuticals · Phase 3
- TabelecleucelPierre Fabre Medicament · Atara Biotherapeutics · Phase 2
- STC-15STORM Therapeutics LTD · Phase 1/2
- IvonescimabAkeso · Summit Therapeutics · Phase 2
- OKN4395Epkin · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Feb 2026 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | |
| Phase 1Completed | 15 Oct 2021 | MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. | |
| Phase 1Terminated | 13 Nov 2023 | A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026